Innoviva Total Assets 2010-2023 | INVA

Innoviva total assets from 2010 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
Innoviva Annual Total Assets
(Millions of US $)
2022 $1,231
2021 $926
2020 $1,000
2019 $725
2018 $548
2017 $367
2016 $379
2015 $409
2014 $522
2013 $681
2012 $369
2011 $259
2010 $331
2009 $181
Innoviva Quarterly Total Assets
(Millions of US $)
2023-09-30 $1,188
2023-06-30 $1,118
2023-03-31 $1,130
2022-12-31 $1,231
2022-09-30 $1,328
2022-06-30 $1,138
2022-03-31 $1,107
2021-12-31 $926
2021-09-30 $887
2021-06-30 $789
2021-03-31 $1,088
2020-12-31 $1,000
2020-09-30 $922
2020-06-30 $880
2020-03-31 $788
2019-12-31 $725
2019-09-30 $676
2019-06-30 $642
2019-03-31 $590
2018-12-31 $548
2018-09-30 $278
2018-06-30 $339
2018-03-31 $277
2017-12-31 $367
2017-09-30 $391
2017-06-30 $372
2017-03-31 $392
2016-12-31 $379
2016-09-30 $371
2016-06-30 $378
2016-03-31 $388
2015-12-31 $409
2015-09-30 $438
2015-06-30 $462
2015-03-31 $489
2014-12-31 $522
2014-09-30 $554
2014-06-30 $606
2014-03-31 $605
2013-12-31 $681
2013-09-30 $666
2013-06-30 $595
2013-03-31 $592
2012-12-31 $369
2012-09-30 $384
2012-06-30 $399
2012-03-31 $218
2011-12-31 $259
2011-09-30 $283
2011-06-30 $303
2011-03-31 $315
2010-12-31 $331
2010-09-30 $213
2010-06-30 $232
2010-03-31 $250
2009-12-31 $181
2009-09-30 $183
2009-06-30 $206
2009-03-31 $215
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.992B $0.331B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.189B 121.76
Novo Nordisk (NVO) Denmark $553.986B 45.64
Johnson & Johnson (JNJ) United States $389.835B 15.52
Merck (MRK) United States $328.029B 86.30
AbbVie (ABBV) United States $314.591B 16.03
Novartis AG (NVS) Switzerland $220.226B 15.26
AstraZeneca (AZN) United Kingdom $204.098B 18.09
Pfizer (PFE) United States $156.744B 15.17
Sanofi (SNY) $123.368B 11.11